Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ohno, Shoko ^a   Yokoi, Hideki ^a   Mori, Kiyoshi ^a   Kasahara, Masato ^b   Kuwahara, Koichiro ^a   Fujikura, Junji ^a   Naito, Masaki ^a   Kuwabara, Takashige ^a,c   Imamaki, Hirotaka ^a   Ishii, Akira ^a   Saleem, Moin A ^d   Numata, Tomohiro ^a,e   Mori, Yasuo ^a   Nakao, Kazuwa ^a   Yanagita, Motoko ^a   Mukoyama, Masashi ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CACNA1B PROTEIN, MOUSE; CALCIUM CHANNEL N TYPE; OMEGA CONOTOXIN;

ANIMAL; BLOOD PRESSURE; CELL CULTURE; CYTOLOGY; DIABETIC NEPHROPATHY; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENE KNOCKOUT; GENETICS; GLUCOSE BLOOD LEVEL; KIDNEY DISTAL TUBULE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PODOCYTE;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CALCIUM CHANNELS, N-TYPE; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; GENE KNOCKOUT TECHNIQUES; KIDNEY TUBULES, DISTAL; MICE; OMEGA-CONOTOXINS; PODOCYTES;

EID: 84974657776     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep27192     Document Type: Article

References (39)

1. Ritz, E. & Orth, S. R. Nephropathy in patients with type 2 diabetes mellitus. N. Engl. J. Med. 341, 1127-1133 (1999).
2. Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456-1462 (1993).
3. Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
4. Vejakama, P. et al. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 55, 566-578 (2012).
5. Davila, H. M. Molecular and functional diversity of voltage-gated calcium channels. Ann. N. Y. Acad. Sci. 868, 102-117 (1999).
6. Hofmann, F., Biel, M. & Flockerzi, V. Molecular basis for Ca2+ channel diversity. Annu. Rev. Neurosci. 17, 399-418 (1994).
7. Ertel, E. A. et al. Nomenclature of voltage-gated calcium channels. Neuron 25, 533-535 (2000).
8. Minami, J., Ishimitsu, T., Higashi, T., Numabe, A. & Matsuoka, H. Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients. Hypertens. Res. 21, 215-219 (1998).
9. Kojima, S., Shida, M. & Yokoyama, H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens. Res. 27, 379-385 (2004).
10. Katayama, K. et al. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo-and microalbuminuria. Kidney Int. 70, 151-156 (2006).
11. Fujita, T. et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 72, 1543-1549 (2007).
12. Konno, Y. & Kimura, K. Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles. Int. Heart J. 49, 723-732 (2008).
13. Fan, Y. Y. et al. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. J. Hypertens. 28, 1034-1043 (2010).
14. Konda, T., Enomoto, A., Matsushita, J., Takahara A. & Moriyama, T. The N-and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 101, 1-13 (2005).
15. Homma, K. et al. Renal microcirculation and calcium channel subtypes. Curr. Hypertens. Rev. 9, 182-186 (2013).
16. Zhou, X., Ono, H., Ono, Y. & Frohlich, E. D. N-and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J. Hypertens. 20, 993-1000 (2002).
17. Ino, M. et al. Functional disorders of the sympathetic nervous system in mice lacking the ? 1B subunit (Cav 2.2) of N-type calcium channels. Proc. Natl. Acad. Sci. USA 98, 5323-5328 (2001).
18. Loeffler, I. & Wolf, G. Transforming growth factor-? and the progression of renal disease. Nephrol. Dial. Transplant. 29, 137-145 (2014).
19. Kuwabara, T. et al. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. Diabetologia 55, 2256-2266 (2012).
20. Brosius, F. C. 3rd et al. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2503-2512 (2009).
21. Breyer, M. D. et al. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 16, 27-45 (2005).
22. Seong, E., Saunders, T. L., Stewart, C. L. & Burmeister, M. To knockout in 129 or in C57BL/6: that is the question. Trends Genet. 20, 59-62 (2004).
23. Takahashi, E. et al. Increased glucose tolerance in N-type Ca2+ channel ? 1B-subunit gene-deficient mice. Int. J. Mol. Med. 15, 937-944 (2005).
24. De Marinis, Y. Z. et al. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N-and L-type Ca2+ channel-dependent exocytosis. Cell Metab. 11, 543-553 (2010).
25. Yamada, Y. et al. Inhibition of N-type Ca2+ channels ameliorates an imbalance in cardiac autonomic nerve activity and prevents lethal arrhythmias in mice with heart failure. Cardiovasc. Res. 104, 183-193 (2014).
26. Mori, Y. et al. Ca2+ channel ? 1B subunit (CaV 2.2) knockout mouse reveals a predominant role of N-type channels in the sympathetic regulation of the circulatory system. Trends Cardiovasc. Med. 12, 270-275 (2002).
27. Lei, B. et al. N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition. J. Pharmacol. Sci. 119, 359-367 (2012).
28. Ott, C. et al. Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. Br. J. Clin. Pharmacol. 75, 129-135 (2013)
29. Hayashi, K. et al. Role of actions of calcium antanogists on efferent arterioles-with special reference to glomerular hypertension. Am. J. Nephrol. 23, 229-244 (2003).
30. Susztak, K., Raff, A. C., Schiffer, M. & Bottinger, E. P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55, 225-233 (2006).
31. Makino, H. et al. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia 49, 2514-2524 (2006).
32. Ogawa, Y. et al. Natriuretic Peptide receptor guanylyl cyclase-a protects podocytes from aldosterone-induced glomerular injury. J. Am. Soc. Nephrol. 23, 1198-1209 (2012).
33. Yokoi, H. et al. Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int. 73, 446-455 (2008).
34. Naito, M. et al. Therapeutic impact of leptin on diabetes, diabetic complications, and longevity in insulin-deficient diabetic mice. Diabetes 60, 2265-2273 (2011).
35. Yokoi, H. et al. Pleiotrophin triggers inflammation and increased peritoneal permeability leading to peritoneal fibrosis. Kidney Int. 81, 160-169 (2012).
36. Saleem, M. A. et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J. Am. Soc. Nephro.l 13, 630-638 (2002).
37. Koga, K. et al. MicroRNA-26a inhibits TGF-beta-induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy. Diabetologia 58, 2169-2180 (2015).
38. Aritomi, S. et al. Expression of N-type calcium channels in human adrenocortical cells and their contribution to corticosteroid synthesis. Hypertens. Res. 34, 193-201 (2011).
39. Aritomi, S., Niinuma, K., Ogawa, T., Konda, T. & Nitta, K. Effects of an N-type calcium antagonist on angiotensin II-renin feedback. Am. J. Nephrol. 33, 168-175 (2011).